Pegylated Interferon Lambda w/wo Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

-
Investigator: Mandana Khalili, MD
Sponsor: Bristol-Myers Squibb Company

Location(s): South Korea; Japan; India; Singapore; Belgium; Finland; France; Greece; Italy; Netherlands; Russia; United Kingdom; Mexico; Argentina; Brazil; Chile; Canada; Australia; New Zealand

Description

The purpose of this study is to determine if 24 weeks of treatment with Pegylated Interferon Lambda plus Ribavirin and 12 weeks of treatment with Pegylated Interferon Lambda plus Ribavirin and Daclatasvir will be safe and effective for treatment of hepatitis C compared to 24 weeks of treatment with Pegylated Interferon Alfa-2a plus Ribavirin.